These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11957743)

  • 1. Pulmonary disposition of budesonide from liposomal dry powder inhaler.
    Joshi M; Misra AN
    Methods Find Exp Clin Pharmacol; 2001 Dec; 23(10):531-6. PubMed ID: 11957743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition kinetics of ketotifen from liposomal dry powder for inhalation in rat lung.
    Joshi M; Misra A
    Clin Exp Pharmacol Physiol; 2003 Mar; 30(3):153-6. PubMed ID: 12603343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nano-liposomal dry powder inhaler of Amiloride Hydrochloride.
    Chougule MB; Padhi BK; Misra A
    J Nanosci Nanotechnol; 2006; 6(9-10):3001-9. PubMed ID: 17048511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis.
    Chennakesavulu S; Mishra A; Sudheer A; Sowmya C; Suryaprakash Reddy C; Bhargav E
    Asian J Pharm Sci; 2018 Jan; 13(1):91-100. PubMed ID: 32104382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal budesonide for dry powder inhaler: preparation and stabilization.
    Joshi MR; Misra A
    AAPS PharmSciTech; 2001 Nov; 2(4):25. PubMed ID: 14727862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in liposomal dry powder formulations: preparation and evaluation.
    Misra A; Jinturkar K; Patel D; Lalani J; Chougule M
    Expert Opin Drug Deliv; 2009 Jan; 6(1):71-89. PubMed ID: 19236209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations.
    Sahib MN; Darwis Y; Peh KK; Abdulameer SA; Tan YT
    Int J Nanomedicine; 2011; 6():2351-66. PubMed ID: 22072872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug delivery to the lungs from dry powder inhalers.
    Newman SP
    Curr Opin Pulm Med; 2003 Apr; 9 Suppl 1():S17-20. PubMed ID: 12974538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic availability and lung deposition of budesonide via three different nebulizers in adults.
    Dahlström K; Thorsson L; Larsson P; Nikander K
    Ann Allergy Asthma Immunol; 2003 Feb; 90(2):226-32. PubMed ID: 12602671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics.
    Chougule M; Padhi B; Misra A
    Int J Nanomedicine; 2007; 2(4):675-88. PubMed ID: 18203434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study comparing the clinical pharmacokinetics, pharmacodynamics, and tolerability of triamcinolone acetonide HFA-134a metered-dose inhaler and budesonide dry-powder inhaler following inhalation administration.
    Argenti D; Shah B; Heald D
    J Clin Pharmacol; 2000 May; 40(5):516-26. PubMed ID: 10806605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of spray dried liposomal dry powder inhaler of Dapsone.
    Chougule M; Padhi B; Misra A
    AAPS PharmSciTech; 2008; 9(1):47-53. PubMed ID: 18446460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deposition and pharmacokinetics of budesonide from the Miat Monodose inhaler, a simple dry powder device.
    Ball DJ; Hirst PH; Newman SP; Sonet B; Streel B; Vanderbist F
    Int J Pharm; 2002 Oct; 245(1-2):123-32. PubMed ID: 12270249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device.
    Fyrnys B; Stang N; Wolf-Heuss E
    Curr Opin Pulm Med; 2001 Apr; 7 Suppl 1():S7-11. PubMed ID: 11385814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of liposomal salbutamol sulfate dry powder inhaler formulation.
    Huang WH; Yang ZJ; Wu H; Wong YF; Zhao ZZ; Liu L
    Biol Pharm Bull; 2010; 33(3):512-7. PubMed ID: 20190418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal dry powders as aerosols for pulmonary delivery of proteins.
    Lu D; Hickey AJ
    AAPS PharmSciTech; 2005 Dec; 6(4):E641-8. PubMed ID: 16408866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redispersible liposomal-N-acetylcysteine powder for pulmonary administration: development, in vitro characterization and antioxidant activity.
    Ourique AF; Chaves Pdos S; Souto GD; Pohlmann AR; Guterres SS; Beck RC
    Eur J Pharm Sci; 2014 Dec; 65():174-82. PubMed ID: 25263567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of budesonide administered via dry-powder inhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler for adults with persistent asthma in managed care settings.
    Weiss KB; Liljas B; Schoenwetter W; Schatz M; Luce BR
    Clin Ther; 2004 Jan; 26(1):102-14. PubMed ID: 14996523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scintigraphic comparison of budesonide deposition from two dry powder inhalers.
    Newman SP; Pitcairn GR; Hirst PH; Bacon RE; O'Keefe E; Reiners M; Hermann R
    Eur Respir J; 2000 Jul; 16(1):178-83. PubMed ID: 10933104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma.
    Shapiro G; Bronsky EA; LaForce CF; Mendelson L; Pearlman D; Schwartz RH; Szefler SJ
    J Pediatr; 1998 Jun; 132(6):976-82. PubMed ID: 9627589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.